ASC618
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ASC618 (also known as AAV2/8 HCB-ET3-LCO BDD FVIII) is an experimental gene therapy for Hemophilia A. It was developed by Applied StemCell Therapeutics and is delivered via a hybrid of adeno-associated virus types 2 and 8. The gene therapy is hoped to be more effective than earlier gene therapies for hemophilia A.
ASC618 (also known as AAV2/8 HCB-ET3-LCO BDD FVIII) is an experimental gene therapy for Hemophilia A. It was developed by Applied StemCell Therapeutics and is delivered via a hybrid of adeno-associated virus types 2 and 8. The gene therapy is hoped to be more effective than earlier gene therapies for hemophilia A.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1252675274 under CC BY-SA 4.0; modifications have been made.